Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized trial comparing injection frequency between Aflibercept and Ranibizumab in Central Retinal Vein Occlusion
2014-001047-21Phase 4Active
- Sponsor
- St. Eriks Eye Hospital
- Start
- Apr 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept, ranibizumab in central retinal vein occlusion (CRVO), sponsored by St. Eriks Eye Hospital. Started Apr 2014; status: active.
02
Drugs
afliberceptranibizumab
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on 2014-001047-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001047-21.